Log In
BCIQ
Print this Print this
 

MK-3682/MK-8742(elbasvir)/MK-5172(grazoprevir) (MK-3682A)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionCombination of MK-3682, a uridine nucleotide analog HCV NS5B polymerase inhibitor, elbasvir, an oral HCV NS5A protein inhibitor, and grazoprevir, an oral HCV NS3/4A protease inhibitor
Molecular Target HCV NS5B polymerase ; HCV NS5A protein
Mechanism of ActionViral protease inhibitor; HCV non-structural protein 5A inhibitor; HCV non-structural protein 5B inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 3 infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today